EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

Home
/
update
/
details

Trinity Biotech Expands Maternal Health Portfolio with Acquisition of Metabolomics Diagnostics

NextEdge Admin

26 Sep 2024

2 min 52 sec

Trinity Biotech plc , a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, announced the acquisition of Metabolomics Diagnostics, a privately held Irish deep-tech company specializing in biomarker-based diagnostics for complex diseases. The deal, valued at approximately $1.3 million, includes over 270,000 Trinity Biotech ADS, cash, and the assumption of liabilities.

This acquisition strengthens Trinity Biotech’s capabilities by integrating Metabolomics Diagnostics' advanced mass spectrometry platform with machine learning-powered bioinformatics. Trinity plans to leverage its New York State-based Immco reference laboratory to commercialize Metabolomics’ PrePsia test in the U.S., with the first revenues anticipated by 2025. The PrePsia test is designed to predict the risk of preeclampsia, a serious maternal health condition, earlier than conventional methods, potentially reducing complications for both mothers and babies. International expansion of the test is also under consideration. Trinity intends to manufacture the test reagents in-house, limiting additional investment needed for commercialization.

John Gillard, President and CEO of Trinity Biotech, highlighted the acquisition as a strategic step in combining the company’s existing manufacturing and regulatory expertise with innovative technology to address urgent maternal health challenges. He emphasized the growing role of artificial intelligence and machine learning in improving human diagnostics, underscoring how the partnership with Metabolomics Diagnostics aligns with Trinity’s broader strategy.

Dr. Robin Tuytten, Director of Metabolomics Diagnostics, noted that Trinity’s regulatory experience and resources would accelerate the introduction of their preeclampsia risk screening technology to the U.S. market. Preeclampsia affects up to 5% of pregnancies and is often diagnosed late, leading to premature deliveries. The PrePsia test has shown in peer-reviewed studies to predict preeclampsia risk as early as week 12, allowing for earlier intervention and reducing the risks of severe health issues for mothers and babies.